Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Burzynski Research Institute, Inc.
HOUSTON, June 27, 2014 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014. Abstracts and presentations are now available to the public in an online supplement in the journal, Neuro-Oncology (Neuro Oncol 2014 June; 16(Suppl 1): i1-i157). The abstract numbers are CT-004, HG-017, and MB-039. The journal's TOC web address is http://neuro-oncology.oxfordjournals.org/content/16/suppl_1.toc.
Highlights from Abstract CT-004
The abstract title is "A phase II study of Antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on Protocol BT-22." Primary malignant brain tumors are the leading cause of cancer-related death in children. This single arm two-stage phase II study evaluated the efficacy and safety of combination of Antineoplastons A10 and AS2-1 (ANP) in children who developed progression of primary brain tumors during standard treatment. A total of 30 children who met the eligibility criteria were treated according to Protocol BT-22 at the Burzynski Clinic (BC). There were 8 cases of glioblastoma (GBM), 11 cases of diffuse intrinsic pontine glioma (DIPG), 6 cases of anaplastic astrocytoma (AA), 2 cases of primitive neuroectodermal tumors (sPNET) and 1 case each of atypical teratoid rhabdoid tumor (ATR), disseminated pilocytic astrocytoma, and medulloblastoma (PNET). Five patients (17%) obtained complete and partial responses; four patients were diagnosed with recurrent DIPG, and one with recurrent AA. The longest survivor is a patient diagnosed with DIPG and disseminated gliosarcoma who remains alive more than 14 years from the treatment start. A small group of patients reported serious toxicity including hypernatremia, somnolence, and hypokalemia.
It is concluded that antineoplastons showed efficacy within an acceptable profile in this group of patients with recurrent, refractory or progressive primary brain tumors.
Titles of Abstracts HG-017 and MB-039
Abstract HG-017: A long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report.
Abstract MB-039: Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report.
The abstracts are scheduled for presentation in the poster session on June 30, 2014 from 6 PM to 8 PM.
About Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc. (OTCBB:BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenetic principles. Research and development efforts are focused on basic research and phase III clinical trials.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the ability to use Antineoplastons A10 and AS2-1. Burzynski Research Institute, Inc. does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.
©2012 PR Newswire. All Rights Reserved.